12 Most Oversold Healthcare Stocks to Buy Now

5. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Year Perf: -35.65%

Analyst Upside: 91.33%

Number of Hedge Fund Holders: 44

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) develops and commercializes human therapeutic drugs using antisense technology. It functions through the Ionis Core segment, which generates a pipeline of drugs through a novel drug discovery platform.

The company began a new chapter as a fully integrated commercial-stage biotechnology company with the recent launch of its first independent medicine, TRYNGOLZA, for familial chylomicronemia syndrome. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) expects three additional independent launches over the next three years, including donidalorsen later in 2025 for hereditary angioedema and olezarsen for severe hypertriglyceridemia in 2026, which is pending Phase 3 results in the second half of 2025.

Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) partners are also on track to launch four Ionis-discovered medicines over the same time period, including several that address broad patient populations. Analysts are bullish on the stock as it is continually advancing the next wave of potentially transformational wholly owned medicines, including ION582 for Angelman syndrome, which is on track to start Phase 3 development in H1 2025. The company’s strong commercial execution, recent achievements, and advancing pipeline position it to deliver growing value for stakeholders, ranking it fifth on our list.